Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon-γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol

Molebogeng X Rangaka,1,2 Yohhei Hamada,1 Trinh Duong,3 Henry Bern,3 Joanna Calvert,3 Marie Francis,1 Amy Louise Clarke,4 Alex Ghanouni,4 Vanessa Hack,1 Ellen Owen-Powell,3 Julian Surey,1 Karen Sanders,3 Helen L Booth,3 Angela Crook,3 Chris Griffiths,6 Robert Horne,4 Heinke Kunst,6 Marc Lipman,7,8 Mike Mandelbaum,9 Peter J White,10,11 Penny Whiting,12 Dominik Zenner,1,13 Ibrahim Abubakar1

ABSTRACT
Introduction The predictive utility for incident tuberculosis (TB) of the purified protein derivative tuberculin skin test and region of difference 1 (RD1)-based interferon-gamma release assays (IGRA) is comparable; and either is recommended to test for latent TB infection (LTBI). Despite associated high costs of IGRA, sites participating in LTBI screening in many high-income settings pragmatically favour IGRA due to its higher specificity and simpler logistics. A new RD1-based skin test, C-Tb, could offer an acceptable and as accurate, cheaper alternative to IGRA. Evaluating the impact of C-Tb on process and patient-related outcomes would provide important information to help guide its use in LTBI testing strategies.

Methods and analysis This is a pragmatic multicentre, open-label, non-inferiority, randomised controlled trial. The trial will assess the initiation of LTBI treatment following a positive result of the randomised test as the primary outcome. Participants will be randomised to receive the C-Tb test (intervention) or IGRA (usual care, control) for initiation of treatment. We will enrol 1530 participants in England aged ≥16 years who are eligible for LTBI testing and treatment according to UK guidance. In the C-Tb arm, skin induration will be assessed 2–3 days after intradermal injection and measured in millimetres of induration. Results of IGRA will be obtained in line with standard practice. Behavioural studies will explore people’s experiences, perspectives and preferences of LTBI testing and treatment. Economic analysis will estimate cost-effectiveness of changes to the diagnostic algorithm for LTBI. The protocol was developed with Patient and Public Involvement (PPI), which will continue throughout the trial.

Strengths and limitations of this study
- This is the first trial to assess the impact of a novel C-Tb test on initiation of treatment for latent tuberculosis infection (LTBI) and process outcomes along the LTBI care cascade.
- Substudies will assess people’s experiences, perspectives and preferences of LTBI testing and treatment and estimate cost and cost-effectiveness of C-Tb, which provide additional evidence to guide testing algorithms.
- The trial will be conducted in England, largely in migrant populations and contacts of TB patients, and thus generalisability to other settings and populations may be limited.
- This is an open-label trial; knowing the allocation group might influence how clinicians manage patients offered preventive treatment.
- Initiation of LTBI treatment for the primary outcome will be based on prescription records.

Ethics and dissemination Ethics approval has been obtained from The NHS Health Research Authority (269485). We will share results of the trial in peer-reviewed journals and conferences.

Trial registration number EudraCT 2019-002592-34; ISRCTN173936038.

INTRODUCTION
Following major declines in tuberculosis (TB) incidence over most of the 20th century, there was a resurgence of the disease in the
UK from the late 1980s to 2005,1 which then stabilised at relatively high levels but has been declining since 2011.2 In 2019, there were 4725 cases notified in England; an incidence of 8.4 cases per 100 000 population, still higher than most other Western European countries and three times as high as in the USA.2 TB disproportionately affects underprivileged communities, such as migrants and homeless people, with a higher incidence of disease and poorer outcomes associated with disadvantage. Addressing TB in these populations is critical for UK to achieve TB elimination.

The diagnosis and treatment of people diagnosed with latent TB infection (LTBI) can reduce the incidence of TB disease by halting progression of LTBI to TB disease, and consequently disrupting transmission in the community.3 LTBI screening and treatment for high risk groups such as new migrants from high TB incidence countries is thus recognised as an essential strategy to halt transmission in England.4

Currently available LTBI tests in England include the interferon-gamma release assays (IGRA) and the purified protein derivative tuberculin skin test (TST).5 The utility of the TST is limited by its poor specificity and sensitivity; and operational challenges.6 Its sensitivity and specificity were estimated to be 70% and 68%, respectively, in immunocompetent adults in a systematic review.7 IGRA while similar sensitivity for LTBI ranges 60%-80%, in contrast has specificity 90%-99%, depending on the population.8 9 Regardless of the differences in accuracy, head-to-head analyses in systematic reviews have shown the predictive performance for subsequent progression to active TB of the two tests to be comparable.8 9 Based on low-quality evidence, the WHO recommended that either test could be used for the diagnosis of LTBI in high-income low-incidence countries.8 10 The LTBI screening programme in the UK pragmatically offers IGRA to new migrants and other groups at high risk for TB infection and disease due to its higher specificity and relatively simpler logistics. The use of IGRA may lead to a smaller number of patients requiring treatment compared with TST without an increase in TB incidence in people who are not treated.11 Furthermore, IGRA does not require a return visit for evaluation of results within a specific time frame for results to remain valid, unlike TST. However, individuals who test positive on IGRA still currently need to return to care for TB investigations and initiation of preventive treatment. The use of IGRA as a primary test for TB infection follows the guidance in the 2016 National Institute for Health and Care Excellence guidelines for managing LTBI.5 Despite its apparent operational simplicity, blood-based detection of LTBI by IGRA is less cost-effective than TST.12 Moreover, although IGRA results could, in theory, be available on the same day, to offset costs, tests are run in batches every 5–14 days depending on local arrangements. This can result in delays in obtaining actionable results and eventual prescription of preventive treatment to eligible individuals, which offsets perceived advantages.

Statens Serum Institut has developed a new skin test (C-Tb), containing the recombinant antigens ESAT-6 (dimer) and CFP10 (monomer) derived from Mycobacterium tuberculosis. Similar to IGRA, and in contrast to the TST, C-Tb appears unaffected by previous BCG vaccination13 and HIV infection,14 both of which affect test performance of TST. Studies reported high overall concordance (94%), and similar sensitivity (74%) and specificity (96%) to the QuantiFERON-TB (QFT) Gold In Tube blood IGRA test.15 16 C-Tb could thus be an immunological improvement on the standard TST, and may therefore offer a cheaper, accurate and acceptable replacement or alternative to IGRA.5 However, there is no evidence of the impact of C-Tb use on patient and process outcomes along the LTBI care pathway from initiation to completion of treatment, or utility when used in current testing algorithms. In a previous study, participants at high risk for TB in an urban area in the US preferred initiation LTBI treatment based on TST results to those of the QFT Gold.17 While accuracy data alone are often used to register new diagnostic tools, any decision to replace a current tool with a new one should additionally consider the impact on patient-important outcomes evaluated in randomised studies.18

Objectives
The overall aim of the RID-TB:DX trial is to evaluate whether C-Tb can be used as an alternative test to the interferon-gamma release assay in the screening of LTBI in England. The primary objective is to determine whether the proportion of participants initiating LTBI treatment based on C-Tb testing is at least as high as that based on the standard-of-care testing. The secondary objectives include: (1) to determine the safety of C-Tb test; (2) to determine the impact of C-Tb test on outcomes along the LTBI care pathway; (3) to evaluate the concordance and diagnostic accuracy of the C-Tb test compared with IGRA; (4) to assess modifiable behavioural factors influencing patient and provider engagement with LTBI testing (includes acceptability and other patient-important outcomes) and (5) to evaluate the cost-effectiveness and budget impact of combinations of new technologies to improve LTBI outcomes.

METHOD AND ANALYSIS
Trial design
A multicentre open-label non-inferiority randomised controlled trial with two parallel groups, C-Tb testing versus standard-of-care testing (IGRA), with 1:1 allocation ratio (figure 1).

Study setting
The trial will recruit from primary and secondary care sites that implement systematic LTBI testing and treatment in England, UK. RID-TB: Diagnostics (Dx) is part of a 5-year programme of work (RID-TB) which is funded by the National Institute for Health Research (NIHR)
Study population
The trial will enrol populations for which LTBI testing and treatment is recommended according to national guidance.19 The trial will largely recruit the priority risk groups for LTBI testing comprising individuals who are contacts of persons diagnosed with active TB and persons screened within the migrant screening programme.19 20 The LTBI migrant screening programme is for new migrants into the UK: individuals should be tested for LTBI if they are aged 16–35 years, entered the UK from a high incidence country (≥150/100 000) or Sub Saharan Africa within the aged 16–35 years, entered the UK: individuals should be tested for LTBI if they are

Inclusion criteria

► Age ≥16 years and ≤65 years.
► Eligible for LTBI testing with IGRA and treatment for LTBI according to UK guidance.
► Willing and able to provide written informed consent.
► Willing and able to comply with the trial, including the randomised test(s) and adherence to follow-up visits.

Exclusion criteria

► Allergy to C-Tb product or any of its constituents.
► Displaying any symptoms or signs of active TB disease.

Interventions

Participants will be randomly allocated to the intervention arm, in which they receive the C-Tb test (Serum Institute of India, India) or the usual care arm, in which IGRA is offered as the test for LTBI. The latest generation QFT IGRA or T-SPOT.TB depending on practice at sites will be offered as the standard of care test (and from now on simply referred to as IGRA).

**Figure 1** Trial schema. *IGRA test will also be done, as per usual care, with those testing C-Tb-negative but IGRA-positive being offered LTBI treatment; such patients who initiate treatment will not count as having achieved the primary endpoint. C-Tb positive being offered LTBI treatment; such patients who initiate treatment will not count as having achieved the primary endpoint. C-Tb negative, or unknown C-Tb result, will be offered treatment before IGRA test results are obtained from designated labs up to 2–4 weeks following batch testing. Therefore, participants with positive C-Tb test results will be offered treatment before IGRA test results are disclosed.

**Intervention arm**
Participants in the intervention arm will be managed based on C-Tb test results. C-Tb test is a skin test based on recombinant ESAT-6 and CFP10 C-Tb. The test will be administered intradermally according to the Mantoux technique.16 Participants will be monitored in clinic for up to 30 min after C-Tb administration. Skin induration will be assessed 2–3 days after placement; induration size of 5 mm or larger is defined as a positive reaction.21 Treatment of LTBI will be offered to those with a positive C-Tb result following a pretreatment assessment as per usual care (see below).

An IGRA will also be performed on all participants in the C-Tb arm in line with standard practice. Phlebotomy for IGRA will precede placement of C-Tb to avoid priming and boosting of results. Clinicians will be blinded to the IGRA result when C-Tb results are evaluated and the treatment decision is made. We will implement a study-specific standard operating procedure to ensure clinicians are blinded to the IGRA result in the rare event this is available at the time of the C-Tb reading. This scenario is highly unlikely since C-Tb results are read within 2–3 days of LTBI testing and IGRA results are obtained from designated labs up to 2–4 weeks following batch testing. Therefore, participants with positive C-Tb test results will be offered treatment before IGRA test results are disclosed. Any participants with IGRA-positive results, who have not yet been offered treatment based on a positive C-Tb result (ie, tested C-Tb negative, or unknown C-Tb result), will be assessed and offered TB preventive treatment as per usual care. Participants with positive C-Tb results but negative IGRA results who have already initiated treatment for LTBI will remain on LTBI treatment.

**Control arm**
Participants in the control arm will be tested with an IGRA alone as per usual care, and managed according to IGRA result. IGRA testing will be conducted using standardised local protocols and results will be interpreted...
as per manufacturer’s recommendations (cut-off for positivity 0.35 IU/L for QFT and eight spots for T-SPOT. TB). Results will be obtained within the usual time frame for that particular clinic/setting and discussed with the participant. Although time frames will be setting specific, we expect this to occur at week 4 (±2 weeks). Treatment of LTBI will be prescribed to those with positive IGRA results once TB disease is ruled out as per national guidance.19

Clinical assessments in usual care
Usual care in both arms comprises clinical assessment at baseline and during follow-up. This includes a brief review of medical history and symptom check and X-ray of the chest to rule out TB disease and further evaluation if this is suspected. Laboratory assessments may include blood testing for haematology, liver and kidney function tests, C reactive protein, HbA1c and glucose, and a blood-borne virus screen will be done for pretreatment assessment of LTBI-positive tests as appropriate within routine care, and may vary slightly by site. Participants with a positive test result either on the C-Tb or IGRA will be reviewed; a detailed history and clinical assessment will be performed, including chest radiography to rule out TB disease prior to initiation of LTBI treatment. The treatment regimen will be decided by attending clinicians according to national guidelines.5 Follow-up of treatment and assessment of completion will be done under usual care.

Outcomes

Primary outcome
The primary outcome is initiation of LTBI treatment (within a defined 24±4 week follow-up period) based on a positive result of the randomised test (ie, C-Tb in the intervention arm and IGRA in the control arm). This will be based on all participants randomised so as to capture the overall impact of C-Tb versus IGRA testing on patient and operational processes. Participants in the C-Tb arm who did not initiate treatment based on a positive C-Tb result but started later based on a positive IGRA result will be considered not to have achieved the primary outcome.

Secondary outcomes
► Safety: local and systemic reactions in participants randomised to the C-Tb test.
► Process outcomes related to impact on the LTBI pathway:
1. For participants randomised to C-Tb, failure to return for C-Tb reading within 2–3 days as recommended by the manufacturer.
2. Acceptance of LTBI treatment among participants with a positive result of the randomised test, as determined by verbal agreement.
3. Initiation of LTBI treatment among those with a positive result of the randomised test, as determined by confirmation of LTBI treatment medications issued by pharmacy.

Table 1 Power calculations for the study assuming varying proportion of IGRA arm participants starting treatment

| Proportion of participants in IGRA arm starting LTBI treatment | Sample size required to achieve 90% power | Power of study, with overall sample size=1530 |
|---------------------------------------------------------------|------------------------------------------|---------------------------------------------|
| 15%                                                          | 1214                                     | 95%                                         |
| 20%                                                          | 1524                                     | 90%                                         |
| 25%                                                          | 1786                                     | 86%                                         |

*Based on a non-inferiority margin of 6% for the absolute difference between IGRA versus C-Tb arm and 5% one-sided significance level.
IGRA, interferon-gamma release assays.

4. Losses to follow-up between diagnosis with LTBI and starting LTBI treatment.
5. Time (days) from testing to starting preventative therapy.
6. Completion of LTBI treatment within a 24±4 week period from starting treatment.

Sample size
A total of 1530 participants will be recruited. This will provide the study 90% power to demonstrate non-inferiority of C-Tb compared with IGRA in terms of the proportion of participants initiating LTBI treatment based on their randomised test result, at 5% one-sided significance level (table 1).22 This is based on a non-inferiority margin of 6% for the absolute difference between arms, and assumes 20% of participants in the IGRA arm decide to start treatment.23 The non-inferiority margin can be reviewed if the event rate in the control arm differs from the original assumption within the non-inferiority frontier framework approach.24

Recruitment
Participants will be identified from primary and secondary care settings in the UK where persons eligible for IGRA LTBI testing and treatment receive care. Contacts of TB patients identified by TB services are assessed at TB clinics for LTBI. Migrants are usually identified when they first register with a general practitioner (GP) or via database held by clinical commissioning groups and/or Flag 4 data provided by NHS Digital to Public Health England.20 25 We will prioritise local authority areas with a high TB incidence (>20 per 100,000 population or over) or a high TB case burden (0.5% of all cases) that have implemented a systematic LTBI testing and treatment programme. Although initial sites and recruitment will be in London, more sites outside London may be engaged following review of recruitment rates in the first study year.

Randomisation and allocation
Participants will be randomised centrally in 1:1 allocation ratio to the two arms, using a computerised algorithm developed and maintained by the Medical Research
Council Clinical Trials Unit at University College London (MRC CTU). Randomisation will be performed using minimisation with a random element of 80%, balanced over a number of clinically important factors. To randomise a participant, data will be entered into the secure online trial database by trial team members at the site who have been trained and authorised to randomise by the MRC CTU. The database will automatically check for eligibility. Only those individuals who meet all eligibility criteria will be able to be randomised.

Blinding
This is an open-label trial. Blinding of participants and care provider to the allocation group is not relevant, since the primary objective of this trial to examine how different modes of tests (skin test versus blood-based assay) affects initiation of LTBI treatment. However, for participants in the C-Tb arm, we will not disclose IGRA results at the time C-Tb results are read and when LTBI treatment is offered.

Data collection methods and management
For the primary outcome, we will confirm treatment initiation by ascertaining that LTBI medication has been issued by pharmacy. The date LTBI treatment issued will be recorded within the database. Data on treatment completion will be collection of patient records at site.

Injection site reactions will be recorded. Expected adverse reactions include, but are not limited to, local pruritus, haematoma and pain. Systemic adverse events will be recorded as well as minor symptoms such as headache or nasopharyngitis, as reported in previous trials of C-Tb.21 A standard checklist will be used by clinicians to prompt participants and ensure adverse events are recorded. In the case of adverse events deemed serious by the attending clinician, additional tests may be done based on clinical grounds.

Information on LTBI pathway process outcomes for participants are collected during follow-up. For those who fail to attend any of the scheduled visits/appointments, attempts to contact participants will be made in line with local practice.

The MRC CTU will be responsible for overall data management and trial management. However, each site will have local responsibility for data entry into the web-based trial database.

We will follow the principles of the UK Data Protection Act to protect the personal data.

Statistical methods
Primary analysis
In analysis of the primary outcome, the proportion of participants initiating LTBI treatment within the 24±4week study follow-up period based on a positive result for their randomised test will be compared between arms. The primary analysis will be based on intention to treat approach. The difference in the proportion in IGRAR versus C-Tb arm will be estimated on the absolute scale using regression models, adjusting for stratification factors. Non-inferiority will be assessed using the upper bound of the 90% CI, corresponding to 5% one-sided significance level. If the upper bound of the CI is less than 6% (the margin of non-inferiority), the C-Tb arm will be considered to be non-inferior to the standard-of-care arm. Of note, if C-Tb is shown to be non-inferior compared with IGRA, it will then be assessed for superiority.

Initiation of LTBI treatment is chosen for the primary outcome since it represents the first step in the pathway of LTBI treatment. The outcome thus captures factors directly related to test performance as well as indirect factors related to the patient, provider or context of care that influence initiation of treatment. In particular, the primary outcome is influenced by the likelihood of a positive LTBI test as well as the likelihood that a participant with a positive test result would subsequently initiate LTBI treatment. Therefore, the interpretation of the primary outcome will need to consider other components derived in the study, including, the secondary outcomes regarding participants’ acceptance and initiation of treatment among those with positive results, concordance rate between C-Tb and IGRA, and diagnostic accuracy estimates of sensitivity and specificity (see below).

Diagnostic accuracy
A head-to-head diagnostic accuracy evaluation of C-Tb versus IGRA will be conducted using data from participants randomised to the C-Tb arm who receive both tests. Diagnostic accuracy estimates for C-Tb including sensitivity, specificity, positive and negative predictive values will be estimated using latent class models.26–28 This will initially be based on data within the RID-TB:Dx trial only, but a meta-analysis approach including other relevant studies is also planned.

Behavioural science evaluation
Quantitative surveys consisting of validated questionnaires that have been adapted for the trial will be used to assess knowledge and beliefs about LTBI, and factors influencing LTBI testing and treatment uptake within the RID-TB:Dx trial.29–31 This work will also assess reasons for declining participation in the diagnostic trial, and participant acceptability and impact of the test in terms of psychosocial and behavioural outcomes. Qualitative work will explore participants’ experiences of LTBI testing and treatment in greater depth to inform the development of an intervention to improve adherence to LTBI treatment. This will use cognitive interviews developed for this substudy as part of the behavioural science work package. This work package provides essential data to understand processes and outcomes deemed important by patients.

Health economic evaluation
This will estimate if expected changes to LTBI diagnosis and/or treatment algorithms are cost-effective from the perspective of the National Health Service, using a health economic model to synthesise data obtained within the entire RID-TB programme and evidence from
Table 2  Definitions of adverse events and reactions

| Term                                      | Definition                                                                                                                                                                                                 |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adverse event (AE)                        | Any untoward medical occurrence in a patient or clinical trial participant to whom a medicinal product has been administered, including occurrences that are not necessarily caused by or related to that product.                      |
| Adverse reaction (AR)                     | Any untoward and unintended response to an investigational medicinal product related to any dose administered.                                                                                               |
| Unexpected adverse reaction               | An adverse reaction, the nature or severity of which is not consistent with the information about the medicinal product in question set out in approved Reference Safety Information for that product in the trial. |
| Serious adverse event (SAE) or serious adverse reaction (SAR) or suspected unexpected serious adverse reaction (SUSAR) | Any adverse event, adverse reaction or unexpected adverse reaction that:                                                                                                                                |
|                                           | ► Results in death                                                                                                                                                                                       |
|                                           | ► Is life-threatening*                                                                                                                                                                                   |
|                                           | ► Requires hospitalisation or prolongation of existing hospitalisation†                                                                                                                                 |
|                                           | ► Results in persistent or significant disability or incapacity                                                                                                                                       |
|                                           | ► Consists of a congenital anomaly or birth defect                                                                                                                                                     |
|                                           | ► Is another important medical condition‡                                                                                                                                                              |

*The term life-threatening in the definition of a serious event refers to an event in which the patient is at risk of death at the time of the event; it does not refer to an event that hypothetically might cause death if it were more severe, for example, a silent myocardial infarction.
†Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisations for a pre-existing condition, that has not worsened or for an elective procedure do not constitute an SAE.
‡Medical judgement should be exercised in deciding whether an AE or AR is serious in other situations. The following should also be considered serious: important AEs or ARs that are not immediately life-threatening or do not result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one of the other outcomes listed in the definition above; for example, a secondary malignancy, an allergic bronchospasm requiring intensive emergency treatment, seizures or blood dyscrasias that do not result in hospitalisation or development of drug dependency.

other sources. We will collect information on the costs participants incur in attending appointments within this trial, to allow potential future analysis from a societal perspective.

Safety reporting
The definitions of the EU Directive 2001/20/EC Article 2 based on the principles of Good Clinical Practice apply to this trial protocol. These definitions are given in table 2. All adverse events, whether expected or not, will be recorded in the patient’s medical notes. Adverse events will be graded using the The Division of AIDS (DAIDS) toxicity grading scale.

Withdrawals from the study due to local and systemic reactions will also be recorded. The investigator must assess the causality of all serious events or reactions in relation to the trial interventions using the predefined definitions. If there is at least a possible involvement of the trial treatment, the MRC CTU clinical reviewer on behalf of the sponsor will make an assessment of the expectedness of the event. Serious adverse events need to be reported to the MRC CTU within 24 hours of the investigator becoming aware of the event from the time of randomisation to the last scheduled follow-up visit at week 4.

Participants may be able to claim compensation for injury caused by their participation in the clinical trial in accordance with the insurance policy held at University College London (UCL).

Monitoring and oversight
The MRC CTU is responsible for overall data management and trial management. An independent data monitoring committee (IDMC) will be formed. The IDMC will be the only group who sees the confidential, accumulating data by randomised arm. The IDMC will review study conduct and safety data regularly. The IDMC will be asked to advise on whether the accumulated data from the trial, together with results from other relevant trials, justifies continuing recruitment of further participants. The IDMC will make recommendations to the programme steering committee (PSC) as to whether the trial should continue in its present form.

The PSC has membership from the Treatment Management Group (TMG) plus independent members (approved by NIHR), including the chair and patient and public involvement (PPI) contributors. The role of the PSC is to provide overall supervision for the trial and provide advice through its independent Chair. The ultimate decision for the continuation of the trial lies with the PSC.

Patient and public involvement
The trial was discussed with the charity TB Alert and two community representatives drawn from a migrant charity and a patient previously treated for LTBI. The behavioural science study will include work that evaluates the influence of patient, provider and institutional behavioural factors that influence engagement with,
and journey through, the LTBI care pathway; this arose following PPI input.

A charity representative and one former patient read versions of the grant proposal and contributed suggestions on study design. At the protocol development stage, the following input was sought from TB Alert: study design, patient information sheet and consent form, patient-facing questionnaires used for behavioural studies.

A specific PPI work plan will be developed. This includes plans to seek and include inputs for: recruitment, patient/public engagement tools, provision of translated materials on LTBI and access to recruitment sites. We will obtain inputs from The RID-TB PPI advisory group consisting of members recruited via social media accounts, TB nurses, TB patient advocates, ex-patient contacts and voluntary/community organisations. We also plan to engage more PPI groups from migrant communities during the trial.

ETHICS AND DISSEMINATION

Ethics approval

Ethics approval has been obtained from the Health Research Authority (HRA) in the UK (269485). Any further substantial amendments will be submitted and approved by the main research ethics committee and HRA.

Consent

Participants will be screened and consented at approved trial sites that are authorised by the MRC CTU to carry out the RID-TB:Dx trial. A copy of the participant information sheet will be given to potential participants who have been referred for LTBI testing (online supplemental appendix A). Written informed consent to enter into the trial and be randomised will be obtained after explanation of the aims, methods, benefits and potential hazards of the trial and before any trial-specific procedures are performed or any blood is taken for the trial (online supplemental appendix B).

Samples for future research will be stored at an accredited laboratory according to the University College London Human Tissue policy (based on the Human Tissue Authority’s guidance) following specific informed consent.

Dissemination

We will report findings of the trial through publications in national and international conferences as well as in peer-reviewed journals. We will follow publication policies used in other clinical trials coordinated by the MRC CTU. All headline authors in any publication arising from the main study or substudies must have made a substantive academic or project management contribution to the work that is being presented. Trial data will be available for sharing by request after the primary publication on approval by the TMG. We will also comply with REF Open Access policy and make a prepublication version of the manuscript available through the UCL Repository.

Protocol version and date

This protocol is an abbreviated version of the original protocol V5.0, December 2020. The start date of the trial is 8 October 2021.

Author affiliations

1Institute for Global Health, University College London, London, UK
2School of Public Health, and Clinical Infectious Disease Research Institute-AFRICA, University of Cape Town, Cape Town, South Africa
3MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, London, UK
4Centre for Behavioural Medicine, UCL School of Pharmacy, London, UK
5University College London Hospitals NHS Foundation Trust, London, UK
6Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
7UCL Respiratory, Division of Medicine, University College London, London, UK
8Royal Free London Hospital NHS Foundation Trust, London, UK
9TB Alert, London, UK
10MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK
11Modelling and Economics Unit, National Infection Service, Public Health England, London, UK
12Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
13Institute of Population Health Sciences, Queen Mary University of London, London, UK

Acknowledgements

We thank the National Institute for Health Research (NIHR) programme officers, University College London (UCL)-NIHR Patient and Public Advisory Group, Medical Research Council Clinical Trials Unit at UCL protocol review committee, and the independent programme steering committee for their support and inputs during the development of the protocol.

Contributors

MXR and IA conceived the study. MXR and IA led the application to secure funding. MXR, IA, JD, YH, BH, JC, MF, ALC, AG, VH, ED-P, JS, KS, HL, AC, CG, RH, MJ, HK, ML, MM, PJW, PW and DZ contributed to the study design. TD and AC provided statistical oversight. MXR, TD and YH drafted and revised the manuscript. All authors contributed critical intellectual input and approved the final manuscript.

Funding

The protocol reported in this publication was supported by the National Institute for Health Research (NIHR) (RP-PG-0217-20009) and will receive support from the NIHR Clinical Research Network. Additional funding for patient and public involvement was provided by the UCLH/UCL Biomedical Research Centre Patient & Public Involvement bursary fund.

Competing interests

None declared.

Patient consent for publication

Not applicable.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Yohhei Hamada http://orcid.org/0000-0002-9845-4267
REFERENCES

1. Abubakar I, Lipman M, Anderson C, et al. Tuberculosis in the UK: time to regain control. BMJ 2011;343:d4281.

2. Public Health England. Tuberculosis in England. 2020 report. Available: https://www.gov.uk/government/publications/tuberculosis-in-england-annual-report [Accessed 13 Jan 2021].

3. Rangaka MX, Cavaco SC, Marais BJ, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015;386:2344–53.

4. Public Health England. Collaborative tuberculosis strategy for England: 2015 to 2020, 2015.

5. National Institute for Health and Care Excellence. Tuberculosis: NICE guidelines 2016, 2016. Available: https://www.nice.org.uk/guidance/ng33 [Accessed 14 Oct 2016].

6. Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3–20.

7. Sadatsafavi M, Shahidi N, Marra F, et al. A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy. J Clin Epidemiol 2010;63:257–69.

8. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva, Switzerland: WHO, 2020.

9. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45–55.

10. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: who guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563–76.

11. Muñoz L, Santin M, Alcaide F, et al. QuantIFERON-TB gold in-tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: a noninferiority clinical trial. Clin Infect Dis 2018;66:396–403.

12. Auguste F, Tsiettsadzeva A, Pink J, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technol Assess 2016;20:1–678.

13. Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One 2013;8:e64215.

14. Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 2016;47:919–28.

15. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011;11:435–44.

16. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 2017;5:259–68.

17. O’Donnell MR, Coe A, Blais C, et al. Acceptance of interferon-gamma release assay by a high-risk urban cohort. Int J Tuberc Lung Dis 2011;15:1334–9.

18. Lord SJ, Staub LP, Bossuyt PMM, et al. Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ 2011;343:d4884.

19. National Institute for Health and Care Excellence. Tuberculosis: NICE guidelines 2016.

20. Public Health England. Latent TB testing and treatment for migrants: a practical guide for commissioners and practitioners 2015.

21. Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 2017;5:259–68.

22. Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open 2016;6:e012994.

23. Sealed Envelope Ltd. Power calculator for binary outcome non-inferiority trials, 2012. Available: https://www.sealedenvelope.com/power/binary-noninferior/

24. Quartagno M, Walker AS, Babiker AG, et al. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation. Trials 2020:21:145.

25. NHS. Flag 4 data for the National latent TB infection (LTBi) programme. Available: https://www.england.nhs.uk/tuberculosis-strategy-for-england-2015-2020/flag-4-data-for-the-national-latent-tb-infection-ltbi-programme/ [Accessed 12 Jan 2021].

26. Menten J, Boelaert M, Lesaffre E. Bayesian meta-analysis of diagnostic tests allowing for imperfect reference standards. Stat Med 2013;32:3598–413.

27. Doan TN, Eisen DP, Rose MT, et al. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: a latent-class analysis. PLoS One 2017;12:e0188631.

28. Perez-Porcuña TM, Pereira-da-Silva HD, Acsaco C, et al. Prevalence and diagnosis of latent tuberculosis infection in young children in the absence of a gold standard. PLoS One 2016;11:e0164181.

29. Horne R, Faaske K, Cooper V, et al. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br J Health Psychol 2013;18:18–30.

30. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. J Psychosom Res 2006;60:831–7.

31. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1–24.

32. U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1, 2017. Available: https://rsc.niaid.nih.gov/sites/default/files/daidsgra dingcorrectedv21.pdf [Accessed 11 Sep 2020].
Supplemental material

Summary Participant Information Sheet for the RID-TB:Dx Clinical Trial

We are inviting you to take part in a study called RID-TB:Dx. This study aims to improve how latent tuberculosis (TB) infection or LTBI is identified within the NHS. If you have LTBI, it means you have been infected with the bacteria that cause tuberculosis (TB), but you are not ill and you do not have any symptoms. Treatment for LTBI can prevent TB.

Thank you for reading this information about the study. Please read the information carefully so you can decide if you are happy to take part. You can discuss it with friends and relatives if you wish. This page gives you an overview; please read the whole document for full details.

The study in brief:
The main study will find out if a new latent TB skin test, called C-Tb, can be used as an alternative to the standard IGRA blood-test to diagnose LTBI. C-Tb is conducted and results checked exactly like with the currently used skintest (results in 2-3 days) but it is as accurate as the “interferon gamma release assay” or IGRA (results in 4 weeks). We will assess how use of the test affects your care, confirm its accuracy, and assess cost compared to IGRA. We will also look at how people feel about LTBI, including how they feel about their diagnosis and any treatment they may have (“behavioural substudy”). As well as this we would like to find out how much it cost you to come to the clinic for the appointments.

This will allow us to see if the C-Tb test offers value for money for the NHS (“health economics” substudy). The behavioural and economics substudies are optional, include only people who agree, and will be questionnaire based (taking up to 10 minutes to complete each time).

Key points about how we do the study:

- We are studying a new skintest for diagnosing LTBI called C-Tb. We think C-Tb can be an equally accurate but less expensive test compared to the currently used IGRA blood test. We want to find out whether we can use C-Tb as an alternative to IGRA to diagnose TB infection.

- This study has 2 groups, one having the IGRA blood test and the other the C-Tb skintest. A computer will randomly allocate you a place in one of two groups, like the “toss of a coin”. Women who are breastfeeding, pregnant or plan to become pregnant during the study will not be invited to participate. Women of childbearing potential will need to agree to have a pregnancy test and to use effective methods of contraception before being allowed to take part.

- Like all medical procedures, the tests used in this study can have unwanted side effects. They are usually minor, if they occur at all. The most common are itching and discomfort on the skin where the test was done.

- If your test results show you have LTBI, you will be referred for treatment to help prevent TB.

- Depending on your test group, this study will require you to visit the clinic one more time than if you were being tested in the usual way for latent TB. The visits will last no more than 60 minutes.

- If you take part in the study, we will also ask if you would like to donate a small (1 tablespoon) amount of blood to be used for future research.

What happens if I am interested in taking part?

If you are interested in learning more about the study, please read the whole document for full details. If you are interested in taking part, we will ask you some questions to see whether you can be tested for LTBI through the study. If not, your doctor will offer your usual care which is the blood test; the C-Tb test is only used as part of the study. However, we would like to ask you, if you agree, to complete some short anonymous questionnaires about your views on testing for latent TB. If you can take part in the study, we will provide you with more information and ask you to sign a consent form once you’ve considered the information. We will give you copies of this information sheet and consent form. If you agree we will also write to your GP to let them know that you have agreed to take part in this research.

If you have any questions about this study, please talk to your doctor or nurse:

Name of doctor or nurse:
Hospital Department:
Hospital:
Address:
Tel: 01234 XXX XXX

Rangaka MX, et al. BMJ Open 2021; 11:e050595. doi: 10.1136/bmjopen-2021-050595
You are free to decide whether or not to take part in this research study. If you choose not to take part, this will not affect the care you get in any way.

- You can stop taking part in the study at any time, without giving a reason.
- Please ask us if there is anything that is not clear or if you would like more information.
1. What is latent TB?
If you have latent TB infection (LTBI), it means you have been infected with the bacteria that cause tuberculosis (TB), but you are not ill and you do not have any symptoms. If you then become ill with “active” TB disease, you could pass TB on to other people. TB bacteria are spread through the air, mainly by coughing. TB can be cured with a combination of different antibiotics which need to be taken for many months (at least 6 months). LTBI can be diagnosed and treated to help prevent TB disease from developing. The treatment for latent TB in England is usually 3 months and fewer drugs are given.

How is latent TB currently diagnosed?
One of two tests is currently used to diagnose latent TB. Both tests look for an immune response (your body’s defence mechanism against germs) to TB, which shows whether you have been exposed to TB bacteria. This reaction is checked in the skin where the test was done. Both tests are considered safe, effects are minor and expected in a small area of the skin where the test was done.

What is the C-Tb test?
The C-Tb test is a new test for TB infection that is administered and checked just like the Mantoux test, but is more accurate than the Mantoux test and has been shown to be as accurate as the IGRA blood test. Because the reaction to the injection needs to be checked by a doctor or nurse, you will need to be able to come to the clinic for this test on a Monday, Tuesday, Wednesday or Friday and then be able to return 2–3 days later. The C-Tb test is considered as safe as the Mantoux test, causing similar effects on the skin where the test was done.

2. What does participation in the study involve?
There will be 2 different groups in the RID-TB:Dx study and everyone who takes part will be in one of them. These are:

1. **C-Tb group**: these people will have the C-Tb skin test (and also an IGRA blood test to ensure they receive the same standard-of-care as usual).

2. **Usual care group**: these people will have only the IGRA blood test.

To ensure the groups receiving each test are as similar as possible at the start of the study, a process called randomisation is used to allocate people to each group. This means a computer will randomly select which group you are in, “like the toss of a coin”. Your doctor will offer you the test(s) according to your allocated group.

If you are a woman of childbearing potential, a urine pregnancy test will be done at screening to ensure you are not pregnant. You will need to agree to use an effective method of contraception for 4 weeks after entering the study.

How will I get my results?
After testing, you will need to return to the clinic to receive the results and discuss what they mean. If the results of either test indicate that you have latent TB, you will be referred to your usual care doctor or nurse, who will discuss treatment with you. You may also be referred for a chest X-ray to rule out active TB and further blood tests as part of usual care. You can get written information about latent TB from your GP or online at www.thetruthabouthb.org/latent-TB

**What tests and checks will be done?**

**Screening:** Women of child bearing potential will need to have a urinary pregnancy test to rule out pregnancy. This may need to be repeated if the screening checks are done on a different day to the day of the LTBI test.

**Day 1:** On the test day, if you have been allocated the C-Tb arm, we will administer the C-Tb test into your arm. You will be monitored in the clinic for up to 30 minutes after it has been administered – this will be alongside the other study activities being carried out. We will take 8ml (about one teaspoon) of blood for the IGRA test as usual. This includes enough blood to repeat the test if it does not work. We will also ask if you will give an additional blood sample of 13.5ml (about one tablespoon) to be stored for future research. This includes blood for
future genetic testing to improve the diagnosis of TB. If you do not want to give your permission for additional blood you can still take part in the main study.

Day 3-4: If you have the C-Tb test, you will be asked to visit the clinic 2-3 days later for the result to be reviewed. This is an extra visit for people in this group. If the test is positive, referral for further evaluation for treatment will be made on this visit; you will not wait until the results of the blood test.

Week 2-4: Your IGRA test result will be ready about 4 weeks after testing. We will give you a date to return to the clinic for results to be reviewed and discussed as usual. IGRA results that do not match C-Tb results will also be discussed; if the IGRA test is positive you will be offered treatment.

We may contact you about 6 months after your tests, to see how you are doing and talk about whether you had any treatment to prevent TB.

Each time you come to the clinic we will screen you for active TB, and also ask you about any other symptoms and illnesses that you have had. We will also ask you about any other health services that you have used since the last clinic visit.

Why am I being asked to take part?
Your doctor has recommended that you should have a LTBI test as you may be eligible for treatment for LTBI. We are conducting the study in your health authority area, it has agreed for us to invite anyone locally who would benefit from a latent TB test to take part.

What are the risks or disadvantages to taking part?
As with usual testing, there is a risk of mainly localised side effects. If you are in the C-Tb group, you will have an extra clinic visit than usual. Although we think C-Tb is as accurate as the IGRA, your doctor will also offer you the blood test at the same time to ensure you receive the same standard-of-care as you would normally.

What are the benefits to taking part?
The are no direct benefits to participating in this study. However, by taking part in this study, you might help us improve diagnosis and care for other people who may be at risk from latent TB or TB disease.

3. What are my rights and care during the study?

What if I experience side effects?
If you become concerned about any side effects during the study, please tell the study staff as soon as possible.

What if my situation changes?
You may withdraw from the study at any time, or from particular aspects of the study. This will not affect the standard-of-care you receive. If you have particular concerns, however, we would ask that you talk to your study doctor or nurse first to see if they can help.

What if I have any serious concerns?
If you have any concerns about the way you have been approached or treated during the study, please talk to your study doctor or nurse. If you are still unhappy, or if you wish to complain, please use the normal NHS complaints process. If you are harmed by taking part in the study, or if you are harmed because of someone’s negligence, then you may be able to take legal action.

What if new information becomes available during the course of the study?
Sometimes during a study, new information becomes available about the tests that are being studied. If this happens, your doctor will tell you about it and discuss with you whether you want to continue the study. If you decide to stop taking part in the study, your doctor will arrange for your care to continue outside of the study.

What happens if the RID-TB:Dx study stops early?
Very occasionally a study is stopped early. If it happens, the reasons will be explained to you and your doctor will arrange for your care to continue outside of the study.

4. What happens to my information and results from the study?

How will we use information about you?
We will need to use information from you (and your medical records if you agree to this) for this research project. This information will include your:
- initials
- NHS number
- name
- date of birth

People will use this information to do the research or to check your records to make sure that the research is being done properly.
People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead. We will keep all information about you safe and secure. Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study.

What are your choices about how your information is used?

You can stop being part of the study at any time, without giving a reason (unless you have agreed to give reasons as part of our behavioural substudy), but we will keep information about you that we already have. If you choose to stop taking part in the study, we would like to continue collecting information about your health from central NHS records/your hospital/your GP. If you do not want this to happen, tell us and we will stop.

We need to manage your records in specific ways for the research to be reliable. This means that we won’t be able to let you see or change the data we hold about you.

If you agree to take part in this study, you will have the option to take part in future research using the additional blood stored for future research. This includes blood for future genetic testing to improve the diagnosis of TB. Your blood will be stored with a code number, the link to your name will only be known to the researchers working on this study.

Where can you find out more about how your information is used?

You can find out more about how we use your information through the following ways:

- The Medical Research Council (MRC) Clinical Trials Unit (CTU) Website [www.ctu.mrc.ac.uk/general/privacy-policy](http://www.ctu.mrc.ac.uk/general/privacy-policy)
- HRA Website [https://www.hra.nhs.uk/information-about-patients/](https://www.hra.nhs.uk/information-about-patients/)
- www.hra.nhs.uk/patientdataandresearch
- by asking one of the research team

What will happen to the results of the RID-TB:Dx study?

When the study is completed, we will publish a summary of the results on the website of the MRC CTU at University College London (UCL): [http://www.ctu.mrc.ac.uk](http://www.ctu.mrc.ac.uk). We will also publish the results in a medical journal, so that other doctors can see them. You can ask your doctor for a copy of any publication. We will also share and publish the results in forms suggested by patient advocacy groups involved with this study. Your identity and any personal details will be kept confidential. No named information about you will be published in any report of this study.

5. Study partners and contacts

Who is organising and funding the study?

This study is organised by the MRC CTU at UCL on behalf of The Whittington NHS Trust. The MRC CTU at UCL has run trials for many years. The study coordination, data collection and analysis and administration will be provided by the MRC CTU at UCL. You can find out more about us at [www.ctu.mrc.ac.uk](http://www.ctu.mrc.ac.uk).

Your doctor is not receiving any money or other payment for asking you to be part of the study. University College London has overall responsibility for the conduct of the study. We are responsible for ensuring the study is carried out ethically and in the best interests of the study participants. A patient representative has been involved in the design of this study and in writing this information.

Who has reviewed the RID-TB:Dx study?

The study has been reviewed by scientists. It has been approved by the Research Ethics Committee of London Harrow, and the National Institute of Health Research (NIHR) who are the funders of the study. It has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA), as well as by the NHS Health Research Authority (HRA) and the hospital’s Research and Development Office.

Who can I contact for further information?

If you want further information about the RID-TB:Dx study, contact your study doctor or nurse (see below).

More information is also available on our website [insert study website or address for study page on MRC CTU at UCL website].

Thank you for taking the time to consider taking part in this study.
(End)
# APPENDIX B: TEMPLATE INFORMED CONSENT FORM (ICF)

(To be presented on local headed paper)

Version 4.0 16 Dec 2020

| Centre Name & Number |  |
|----------------------|--|
| Patient ID Number | |
| Name of Researcher | |

|   | I have read and understood the information sheet for the RID-TB:Dx research study [Insert Info: Date & Version] and have been given a copy to keep. I have had the chance to ask questions about the project and discuss it with the study staff. I have received answers to all of my questions. | Initial to Agree |
|---|---|---|
| 1 | I understand that my medical notes may be looked at by individuals from the Medical Research Council (MRC) Clinical Trials Unit (CTU), or from regulatory authorities where it is relevant to my taking part in this research. I give permission for these individuals to access my records. I understand that my confidentiality will be maintained. |  |
| 2 | I understand that participation in this trial is voluntary and that I am free to withdraw from the trial at any time, without giving any reason and without my medical care or legal rights being affected. |  |
| 3 | I understand that I may not benefit directly by participating in this study but that the research may help people with this condition in the future. |  |
| 4 | In order to follow-up on my health status after my participation in the trial, I give permission for my personal details (such as NHS number, name and date of birth) to be used to obtain information about my health status from records held by NHS Digital, Public Health England, the National TB register, or any applicable national or NHS information system. I understand that this information may be obtained about me during the study and after (up to 10 years). |  |
| 5 | Women of child bearing potential only: |  |
| 6a | I understand that I will have a urine pregnancy test at screening (and on the day of my LTBI test if this is done on a different day to my screening checks) and that if this is positive I will not be invited to take part in the study. |  |
| 6b | I agree to use an effective method of contraception (as discussed with my clinician) for the duration of the study (i.e. up to the week 4 scheduled visit). |  |

Optional Items:

If you do not wish to give this permission, do not put your initials in the box – you can still take part in the study

|   | I agree for my GP to be informed of my participation in the research study. |  |
|---|---|---|
| 7 | Yes ☐ No ☐ |  |

|   | I agree to participate in the Behavioural Sub-study and to complete the questionnaires. |  |
|---|---|---|
| 8 | Yes ☐ No ☐ |  |

|   | I agree to participate in the Health Economics Sub-study and to complete the questionnaires. |  |
|---|---|---|
| 9 | Yes ☐ No ☐ |  |
10 I give permission for my left-over routine blood samples to be stored and made available for future research. I understand that these samples will be stored appropriately and I will not be identified by name. I understand that some of these projects may be approved separately and carried out by researchers other than the MRC CTU. I understand that the results of these research projects are unlikely to have any implications for me personally.

Yes ☐ No ☐

11 I give permission for a blood sample to be taken and used for future research, including genetic testing to improve the diagnosis of TB. I understand that these projects may be approved separately and carried out by researchers other than the MRC CTU. I understand that I will not receive any personal results from these non-routine tests unless the researchers discover genetic information which has significant implications for my ongoing care, my future health or for that of my family. I understand that if this happens, my doctor will contact me.

Yes ☐ No ☐

12 I agree to take part in the RID-TB:Dx study.

Signature Page

| Name of Participant (BLOCK CAPITALS) | Date (Day/month/year) | Signature (or thumbprint) |
|-------------------------------------|-----------------------|---------------------------|

| Name of Witness (BLOCK CAPITALS) | Date (Day/month/year) | Signature (if thumbprint used above) |
|----------------------------------|-----------------------|--------------------------------------|

| Name of person taking consent (BLOCK CAPITALS) | Date (Day/month/year) | Signature |
|-------------------------------------------------|-----------------------|-----------|

IMPORTANT: Signed original to be kept in the Investigator Site File
One copy to be given to the participant
One copy to be kept with the participant’s medical notes